Hanna Seppänen
@hannaseppanen.bsky.social
Upper gi-surgeon: pancreatic and gastric tumor surgery.
Adj Prof, founder of Pancreative-research group in Helsinki University Hospital, Finland @HUS_fi @helsinkiuni @Pancreative_fi
Adj Prof, founder of Pancreative-research group in Helsinki University Hospital, Finland @HUS_fi @helsinkiuni @Pancreative_fi
Reposted by Hanna Seppänen
Distribution of the NCCN stages of #PancreaticCancer ?
16,412 pts (2017-2022) 🇳🇱
👉23% primary resectable
👉 8% borderline resectable
👉 11% locally advanced
👉 58% metastatic
⏩️ academic.oup.com/bjs/article/11…
16,412 pts (2017-2022) 🇳🇱
👉23% primary resectable
👉 8% borderline resectable
👉 11% locally advanced
👉 58% metastatic
⏩️ academic.oup.com/bjs/article/11…
July 11, 2025 at 8:59 PM
Distribution of the NCCN stages of #PancreaticCancer ?
16,412 pts (2017-2022) 🇳🇱
👉23% primary resectable
👉 8% borderline resectable
👉 11% locally advanced
👉 58% metastatic
⏩️ academic.oup.com/bjs/article/11…
16,412 pts (2017-2022) 🇳🇱
👉23% primary resectable
👉 8% borderline resectable
👉 11% locally advanced
👉 58% metastatic
⏩️ academic.oup.com/bjs/article/11…
Yesterday my student Matilda Roos-Mattila defended her thesis on ”Stromal Inflammatory Markers and Drug Sensitivities in Pancreatic Malignancies” with potential help for PDAC patients (stay tuned). Prestige opponent prof Johanna Ivaska from Turku University
March 15, 2025 at 12:27 PM
Yesterday my student Matilda Roos-Mattila defended her thesis on ”Stromal Inflammatory Markers and Drug Sensitivities in Pancreatic Malignancies” with potential help for PDAC patients (stay tuned). Prestige opponent prof Johanna Ivaska from Turku University